US20040247867A1 - Hydrogel string medical device - Google Patents

Hydrogel string medical device Download PDF

Info

Publication number
US20040247867A1
US20040247867A1 US10/809,140 US80914004A US2004247867A1 US 20040247867 A1 US20040247867 A1 US 20040247867A1 US 80914004 A US80914004 A US 80914004A US 2004247867 A1 US2004247867 A1 US 2004247867A1
Authority
US
United States
Prior art keywords
hydrogel
catheter
string
gelation
delivery device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/809,140
Other languages
English (en)
Inventor
Hassan Chaouk
Bruktawit Asfaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocure Inc
Original Assignee
Biocure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocure Inc filed Critical Biocure Inc
Priority to US10/809,140 priority Critical patent/US20040247867A1/en
Assigned to BIOCURE, INC. reassignment BIOCURE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASFAW, BRUKTAWIT T., CHAOUK, HASSAN
Publication of US20040247867A1 publication Critical patent/US20040247867A1/en
Priority to US11/368,240 priority patent/US7666339B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • A61B17/1219—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices expandable in contact with liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
    • A61B2017/00641—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closing fistulae, e.g. anorectal fistulae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
    • A61B2017/00646—Type of implements
    • A61B2017/00654—Type of implements entirely comprised between the two sides of the opening
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831—Material properties
    • A61B2017/00893—Material properties pharmaceutically effective
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2913—Rod, strand, filament or fiber

Definitions

  • the invention relates to a hydrogel string useful as a medical device and to a method for forming a hydrogel string.
  • the method utilizes a device in which a prepolymer composition is brought into contact with a gelation initiator to form a hydrogel, which is then extruded from the device as the hydrogel string.
  • Hydrogels have been shown to be useful for a number of biomedical applications. For example, there are many instances in which an appropriate hydrogel biomaterial has been shown to be useful in repair of tissues and in augmentation of tissues, such as repair of defects and conditions in a tissue caused by disease, injury, or aging, repair of congenital defects and conditions in a tissue, and augmentation of tissues to provide a desirable functional, reconstructive, or cosmetic change.
  • Bulking of the lower esophageal sphincter has been used for treatment of gastroesophageal reflux disease (GERD). Vesicoureteral reflux can be treated by endoscopic injection of a bulking agent in the submucosal space.
  • incontinence can be treated by injection of a bulking agent into the submucosa of the urethra, in order to “beef up” the area and improve muscle tone.
  • Spinal disc replacement or augmentation is another application where the use of hydrogels has been explored.
  • hydrogel embolic agents are useful for a variety of bioapplications, such as occluding blood vessels, occluding other body lumens such as fallopian tubes, filling aneurysm sacs, as arterial sealants, and as puncture sealants. Embolization of blood vessels is performed for a number of reasons, e.g.
  • AMMs arteriovenous malformations
  • AVFs arteriovenous fistulas
  • Hydrogels have also been developed and used for drug delivery.
  • Hydrogel biomaterials can be preformed, such as hydrogel discs for drug delivery, or hydrogel microspheres for embolization. Hydrogels can also be formed in situ- at the site of embolization, for example.
  • Each form has its advantages and disadvantages. Solid, preformed articles can be difficult to administer; larger articles can require invasive surgery and smaller articles can migrate after implantation. For example, solid particles and microspheres are generally unsuitable for filling aneurysms, particularly wide-necked aneurysms, due to migration of the particles or microspheres out of the sac.
  • Liquid, in situ formed materials can be flushed from the site during implantation.
  • Another disadvantage is that the liquid may not form a cohesive solid mass, and bits of the hydrogel may be sloughed off over time.
  • hydrogel string that is formed at the time of delivery would be useful for many biomedical applications.
  • the string would be available in the desired length, since it would be formed at the time of use.
  • FIG. 1 is a schematic of one embodiment of the hydrogel string delivery device.
  • FIG. 2 is a schematic of the distal tip of one embodiment of the hydrogel string delivery device, showing the mixing chamber and the extruded hydrogel string.
  • Hydrogel refers to a material having an aqueous phase with an interlaced polymeric component, with at least 10% to 90% of its weight as water.
  • Macromer means a crosslinkable macromonomer.
  • “Microcatheter” means a catheter having a distal tip size of about 4 French or smaller.
  • Prepolymer means a macromer or polymer composition that forms a hydrogel upon exposure to some initiation event.
  • the invention is a hydrogel string that is useful as a medical device.
  • the invention is a method for forming a hydrogel string.
  • the method utilizes a delivery device in which the hydrogel is formed within the device and extruded from the device at the intended site.
  • the hydrogel can be formed in any manner, generally from a prepolymer that is brought into contact with an initiator within the device.
  • the prepolymer component(s) are fed to the device from syringes or other reservoirs and the string can be formed and extruded having a length as long as desired.
  • the string is formed by bringing together two liquid components that form a hydrogel when combined in the device, and then extruding or pushing the string out of the device.
  • the string can be formed by having an initiator within the device, wherein the prepolymer contacts the initiator, the hydrogel forms, and is then extruded from the device.
  • the initiator could be part of the tip of a catheter.
  • the method involves bringing together two liquid components within a dual lumen catheter, having a mixing tip on the end.
  • the two liquid components may each contain prepolymer, whereupon the prepolymers form the hydrogel when mixed.
  • the two liquid components may each contain prepolymers and one or both components may contain a crosslinking initiator.
  • the prepolymer may be contained in only one component, while one or both components contain a crosslinking initiator.
  • the prepolymer may be in one component, while the initiator is in the other component. In any event, a hydrogel is formed when the components mix in the mixing tip.
  • the mixing and hydrogel formation is achieved within the lumen of the delivery catheter (or within the needle of a syringe).
  • the hydrogel exits the catheter distal end as a string of fully or partially crosslinked hydrogel.
  • the hydrogel string is formed from one or more prepolymers that can gel to form a hydrogel.
  • examples include hydrogels formed from macromers, as described in WO 01/68720 to BioCure, Inc. and U.S. Pat. No. 5,410,016 to Hubbell et al.
  • Gelation of the prepolymer can be via a number of mechanisms, such as physical crosslinking or chemical crosslinking.
  • Physical crosslinking includes, but is not limited to, complexation, hydrogen bonding, desolvation, Van der wals interactions, and ionic bonding.
  • Chemical crosslinking can be accomplished by a number of means including, but not limited to, chain reaction (addition) polymerization, step reaction (condensation) polymerization and other methods of increasing the molecular weight of polymers/oligomers to very high molecular weights.
  • Chain reaction polymerization includes, but is not limited to, free radical polymerization (thermal, photo, redox, atom transfer polymerization, etc.), cationic polymerization (including onium), anionic polymerization (including group transfer polymerization), certain types of coordination polymerization, certain types of ring opening and metathesis polymerizations, etc.
  • Step reaction polymerizations include all polymerizations which follow step growth kinetics including but not limited to reactions of nucleophiles with electrophiles, certain types of coordination polymerization, certain types of ring opening and metathesis polymerizations, etc.
  • Other methods of increasing molecular weight of polymers/oligomers include but are not limited to polyelectrolyte formation, grafting, ionic crosslinking, etc.
  • hydrogels can be formed by the ionic interaction of divalent cationic metal ions (such as Ca +2 and Mg +2 ) with ionic polysaccharides such as alginates, xanthan gums, natural gum, agar, agarose, carrageenan, fucoidan, furcellaran, laminaran, hypnea, eucheuma, gum arabic, gum ghatti, gum karaya, gum tragacanth, locust beam gum, arabinogalactan, pectin, and amylopectin.
  • divalent cationic metal ions such as Ca +2 and Mg +2
  • ionic polysaccharides such as alginates, xanthan gums, natural gum, agar, agarose, carrageenan, fucoidan, furcellaran, laminaran, hypnea, eucheuma, gum arabic, gum ghatti, gum karaya, gum traga
  • Multifunctional cationic polymers such as poly(l-lysine), poly(allylamine), poly(ethyleneimine), poly(guanidine), poly(vinyl amine), which contain a plurality of amine functionalities along the backbone, may be used to further induce ionic crosslinks.
  • Block and graft copolymers of water soluble and insoluble polymers exhibit such effects, for example, poly(oxyethylene)-poly(oxypropylene) block copolymers, copolymers of poly(oxyethylene) with poly(styrene), poly(caprolactone), poly(butadiene), etc.
  • prepolymers that contain groups that demonstrate activity towards functional groups such as amines, imines, thiols, carboxyls, isocyanates, urethanes, amides, thiocyanates, hydroxyls, etc.
  • Desirable crosslinkable groups include (meth)acrylamide, (meth)acrylate, styryl, vinyl ester, vinyl ketone, vinyl ethers, etc. Particularly desirable are ethylenically unsaturated functional groups.
  • the method can be used to form a hydrogel string from any prepolymer system wherein a hydrogel can be formed by contacting the prepolymer with an initiator.
  • a hydrogel can be formed by contacting the prepolymer with an initiator.
  • dual polymer systems such as that disclosed in U.S. Pat. No. 6,534,591 to Rhee et al. can be used.
  • the hydrogel can be formed from one or more macromers that include a hydrophilic or water soluble region and one or more crosslinkable regions.
  • the macromers may also include other elements such as one or more degradable or biodegradable regions. A variety of factors-primarily the desired characteristics of the formed hydrogel—determines the most appropriate macromers to use. Many macromer systems that form biocompatible hydrogels can be used.
  • Macromers can be constructed from a number of hydrophilic polymers, such as, but not limited to, polyvinyl alcohols (PVA), polyethylene glycols (PEG), polyvinyl pyrrolidone (PVP), polyalkyl hydroxy acrylates and methacrylates (e.g. hydroxyethyl methacrylate (HEMA), hydroxybutyl methacrylate (HBMA), and dimethylaminoethyl methacrylate (DMEMA)), polysaccharides (e.g. cellulose, dextran), polyacrylic acid, polyamino acids (e.g. polylysine, polyethylmine, PAMAM dendrimers), polyacrylamides (e.g.
  • PVA polyvinyl alcohols
  • PEG polyethylene glycols
  • PVP polyvinyl pyrrolidone
  • HEMA hydroxyethyl methacrylate
  • HBMA hydroxybutyl methacrylate
  • DMEMA dimethylamin
  • polydimethylacrylamid-co-HEMA polydimethylacrylamid-co-HBMA, polydimethylacrylamid-co-DMEMA.
  • the macromers can be linear or can have a branched, hyperbranched, or dendritic structure.
  • Macromers suitable for use in the compositions described herein are disclosed in WO 01/68720 to BioCure, Inc.
  • Other suitable macromers include those disclosed in U.S. Pat. No. 5,410,016 to Hubbell et al., U.S. Pat. No. 4,938,763 to Dunn et al., U.S. Pat. No. 5,100,992 and U.S. Pat. No. 4,826,945 to Cohn et al., U.S. Pat. No. 4,741,872 and U.S. Pat. No. 5,160,745 to De Luca et al, and U.S. Pat. No. 4,511,478 to Nowinski et al.
  • the macromers are those described in WO 01/68720 to BioCure, Inc. These macromers have a PVA backbone and at least two pendant chains containing ethylenically unsaturated groups that can be crosslinked.
  • the crosslinkers are desirably present in an amount of from approximately 0.01 to 10 milliequivalents of crosslinker per gram of backbone (meq/g), more desirably about 0.05 to 1.5 meq/g.
  • the ethylenically unsaturated groups are crosslinked using a two part redox system.
  • One part of the system contains a reducing agent such as a ferrous salt.
  • a ferrous salt can be used, such as, for example, ferrous gluconate dihydrate, ferrous lactate dihydrate, or ferrous acetate.
  • the other half of the system contains an oxidizing agent such as hydrogen peroxide.
  • reducing agents can be used, such as, but not limited to, cuprous salts, cerous salts, cobaltous salts, permanganate, and manganous salts.
  • Ascorbate for example, can be used as a coreductant to recycle the reductant and reduce the amount needed. This can reduce the toxicity of a ferrous based system.
  • Other oxidizing agents that can be used include, but are not limited to, t-butyl hydroperoxide, t-butyl peroxide, benzoyl peroxide, cumyl peroxide, etc.
  • the hydrogel string is formed within and delivered from a delivery device.
  • the device includes or is connected to a reservoir for the prepolymer, and includes the initiator.
  • the device includes a mixing tip, or gelation tip, where the prepolymer contacts the initiator and forms the hydrogel.
  • the device also includes a way to extrude the formed hydrogel out of the device.
  • the preferred embodiment of the delivery device is a catheter.
  • the catheter can be multilumen, especially if the initiator is provided via a second liquid.
  • a catheter having at least two lumens is employed in the method for forming the hydrogel string.
  • a side-by-side dual lumen catheter can be used although a coaxial catheter is preferred.
  • the distal portion of the catheter includes a gelation chamber of sufficient length for the two solutions to mix and form the hydrogel string.
  • one of the lumens or catheters is slidable within the mixing chamber, so that the length of the gelation chamber can be changed.
  • the catheter is a coaxial dual lumen catheter, having a first, or outer, catheter and a second, or inner, catheter.
  • the second catheter is positioned inside the first catheter to form a coaxial dual lumen catheter.
  • the catheters are desirably used with a manifold, which provides for connection between the catheters and reservoirs that the two solutions are delivered from—such as syringes.
  • the device can further include a syringe holder, into which the syringes can be placed so that delivery of the two solutions can be synchronized.
  • a guidewire can be used, if desired, to aid in placement of the catheters.
  • the device 10 includes first catheter 16 , which can be attached to the manifold 20 at its proximal end 18 via a luer adaptor 19 , for example.
  • the manifold 20 includes a syringe adaptor 22 which provides connection (via a luer lock for example) between the interior space 26 of the manifold 20 (which leads into the first, outer catheter) and a syringe (not shown) for the first solution.
  • the second, inner, catheter 30 is sized so that it can be slid inside the first catheter 16 .
  • the second catheter should be sized to allow flow of a solution through the first catheter when the second catheter is in place. In other words, the second catheter should not fit too tightly within the first catheter.
  • the manifold 20 includes a second adaptor 34 to receive the second catheter 30 .
  • This can be a Tuohy-Borst adaptor, through which the second catheter can be inserted.
  • the second catheter 30 is then pushed through the manifold and into and through the first catheter 16 . Accordingly, the second solution delivered through the second catheter 30 does not contact the first solution delivered through the first catheter 16 .
  • a syringe (not shown) is fastened to the second catheter 30 for delivery of the second solution.
  • second catheter 30 terminates some distance before first catheter 16 so that gelation chamber 36 is formed at the distal end of first catheter 16 .
  • gelation chamber 36 is formed at the distal end of first catheter 16 .
  • the first and second syringes are retained within a syringe holder (not shown) which allows synchronized delivery of the two solutions.
  • the manifold would desirably be designed so that the syringes are aligned.
  • a guidewire (not shown) can be used.
  • the first catheter can be a commercially available catheter, such as a FasTracker 325 or Tracker 18 microcatheter. It should be of appropriate size to access the intended site of application.
  • the outer diameter of the first catheter therefore can be of any size, so long as it is appropriate for the application.
  • the presently disclosed device is particularly applicable for neurovascular applications or site selective applications which, in some cases, require microcatheters down to 1.6 Fr or smaller.
  • the practical upper limit to catheter size is about 8 Fr.
  • the first catheter can be a Tracker 18, having an inner diameter of 0.021 inches.
  • the second catheter can have an outer diameter of 0.012 inches, and an inner diameter of 0.009 inches.
  • the space between the first catheter's inner diameter and the second catheter's outer diameter can vary in size.
  • the second catheter may be as small-as about 0.7 Fr.
  • the first catheter can be made of standard catheter materials, typically a polymer such as, for example, polyurethane, polyethylene, silicone, or nylon.
  • the second microcatheter can be made of a polymer but is desirably made of metal such as stainless steel or a binary nickel titanium alloy (nitinol).
  • the second catheter can also be formed from standard catheter plastics but for use as a microcatheter is desirably formed from a metal, such as platinum, a platinum alloy, a nickel alloy, a titanium alloy, and some types of stainless steel (such as 316L stainless steel). Desirably, a binary nickel titanium alloy (nitinol) is used.
  • Some plastics such as polyimide, polyethylene, polyurethane, and PTFE may be useful. The requirements for the fabrication material will depend upon the desired characteristics of the microcatheter, such as flexibility and strength, and the design parameters such as length and diameter. Desirably, medical grade superelastic nitinol is used.
  • the method for forming the hydrogel string is described with respect to filling an aneurysm but the method is applicable to a variety of biomedical applications.
  • the method and string can be used for repair of defects and conditions in a tissue caused by disease, injury, or aging, repair of congenital defects and conditions in a tissue, and augmentation of tissues to provide a desirable functional, reconstructive, or cosmetic change.
  • Examples include bulking of the lower esophageal sphincter for treatment of gastroesophageal reflux disease (GERD), endoscopic injection of a bulking agent in the submucosal space to treat vesicoureteral reflux, treatment of incontinence by injection of a bulking agent into the submucosa of the urethra, in order to “beef up” the area and improve muscle tone, and replacement or augmentation of a spinal disc.
  • GUD gastroesophageal reflux disease
  • the two liquid components may each contain prepolymer, whereupon the prepolymers form the hydrogel when mixed.
  • the two liquid components may each contain prepolymers and one or both components may contain a crosslinking initiator.
  • the prepolymer may be contained in only one component, while one or both components contain a crosslinking initiator.
  • the prepolymer may be in one component, while the initiator is in the other component.
  • the coaxial dual lumen microcatheter described above is used. Since the inner diameter of the inner catheter is so small, the viscosity of the solution delivered through the inner catheter must be low.
  • Solution containing macromer is delivered through the first (outer) catheter; and initiator solution is delivered through the second (inner) catheter.
  • the initiator can be either reductant or oxidant and the other of the pair is delivered with the macromer.
  • Liquid contrast agent can be contained in both solutions.
  • the first (outer) catheter is positioned at the administration site, desirably using a guidewire.
  • the second (inner) catheter is threaded through the first catheter (first removing the guidewire if one has been used).
  • the first and second catheters are connected to syringes or other dispensers holding the two solutions (as described above).
  • the catheters may be part of a delivery device including a manifold and syringe holder, if desired.
  • the method then involves delivering the two solutions which gel in the catheter gelling chamber.
  • the nature of the string 40 in the gelation chamber 36 changes through the length of the gelation chamber 36 .
  • the solutions are first coming into contact and begin to mix. Initiation of gelation begins and the string begins to form.
  • the composition is liquid at the proximal end and gelled at the distal end. Further injection of solutions into the catheters force the string out of the distal tip of the catheter and into the aneurysm, for example.
  • the inner catheter is slidable within the outer catheter. If the operator wants to inject a less gelled composition into the aneurysm, he can slide the inner catheter towards the distal end of the gelation chamber, which means the composition exiting the catheter will be less solid. This may be desirable, for example, in order to fill in the spaces.
  • the method can deliver a composition ranging from a distinct solid string to a semi-solid near liquid.
  • the gelation time of the compositions can be varied from about 0.5 seconds to as long as 10 minutes, and longer if desired.
  • the gelation time will generally be affected by, and can be modified by changing at least the following variables: the initiator system, crosslinker density, macromer molecular weight, macromer concentration (solids content), and type of crosslinker.
  • a higher crosslinker density will provide faster gelation time; a lower molecular weight will provide a slower gelation time.
  • a higher solids content will provide faster gelation time.
  • the gelation time can be designed by varying the concentrations of the redox components. Higher reductant and higher oxidant will provide faster gelation, higher buffer concentration and lower pH will provide faster gelation.
  • the firmness of the formed hydrogel will be determined in part by the hydrophilic/hydrophobic balance, where a higher hydrophobic percent provides a firmer hydrogel.
  • the firmness will also be determined by the crosslinker density (higher density provides a firmer hydrogel), the macromer molecular weight (lower MW provides a firmer hydrogel), and the length of the crosslinker (a shorter crosslinker provides a firmer hydrogel).
  • the swelling of the hydrogel is inversely proportional to the crosslinker density. Generally, no or minimal swelling is desired, desirably less than about 10 percent.
  • Elasticity of the formed hydrogel can be increased by increasing the size of the backbone between crosslinks and decreasing the crosslinker density. Incomplete crosslinking will also provide a more elastic hydrogel.
  • the elasticity of the hydrogel substantially matches the elasticity of the tissue to which the composition is to administered.
  • a contrast agent is a biocompatible (non-toxic) material capable of being monitored by, for example, radiography.
  • the contrast agent can be water soluble or water insoluble.
  • water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.
  • Iodinated liquid contrast agents include Omnipaque®, Visipaque®, and Hypaque-76®.
  • water insoluble contrast agents are tantalum, tantalum oxide, barium sulfate, gold, tungsten, and platinum. These are commonly available as particles preferably having a size of about 10 ⁇ m or less.
  • the contrast agent can be added to one or both of the solutions prior to administration. Both solid and liquid contrast agents can be simply mixed with one or both solutions. Liquid contrast agent can be mixed at a concentration of about 10 to 80 volume percent, more desirably about 20 to 50 volume percent. Solid contrast agents are desirably added in an amount of about 10 to 40 weight percent, more preferably about 20 to 40 weight percent.
  • an effective amount of one or more biologically active agents can be incorporated into the hydrogel string simply by including the agent in one or both solutions. It may be desirable to deliver the active agent from the formed hydrogel. Biologically active agents that it may be desirable to deliver include prophylactic, therapeutic, and diagnostic agents including organic and inorganic molecules and cells (collectively referred to herein as an “active agent” or “drug”). A wide variety of active agents can be incorporated into the hydrogel. Release of the incorporated additive from the hydrogel is achieved by diffusion of the agent from the hydrogel, degradation of the hydrogel, and/or degradation of a chemical link coupling the agent to the polymer. In this context, an “effective amount” refers to the amount of active agent required to obtain the desired effect.
  • active agents examples include, but are not limited to, anti-angiogenic agents, chemotherapeutic agents, radiation delivery devices, such as radioactive seeds for brachytherapy, and gene therapy compositions.
  • Chemotherapeutic agents that can be incorporated include water soluble chemotherapeutic agents, such as cisplatin (platinol), doxorubicin (adriamycin, rubex), or mitomycin C (mutamycin).
  • Other chemotherapeutic agents include iodinated fatty acid ethyl esters of poppy seed oil, such as lipiodol.
  • Cells can be incorporated into the compositions, including cells to encourage tissue growth or cells to secrete a desired active agent.
  • cells that can be incorporated include fibroblasts, endothelial cells, muscle cells, stem cells, etc.
  • Cells can be modified to secrete active agents such as growth factors.
  • Active agents can be incorporated into the compositions simply by mixing the agent with one or both solutions. The active agent will then be entrapped in the hydrogel string.
  • the active agent can be in compound form or can be in the form of degradable or nondegradable nano or microspheres. It some cases, it may be possible and desirable to attach the active agent to the macromer. The active agent may be released from the macromer or hydrogel over time or in response to an environmental condition.
  • peroxide stabilizer in redox initiated systems.
  • peroxide stabilizers are Dequest® products from Solutia Inc., such as for example Dequest® 2010 and Dequest® 2060S. These are phosphonates and chelants that offer stabilization of peroxide systems.
  • Dequest® 2060S is diethylenetriamine penta(methylene phosphonic acid). These can be added in amounts as recommended by the manufacturer.
  • fillers in the compositions such as fillers that leach out of the formed hydrogel over a period of time and cause the hydrogel to become porous. Such may be desirable, for example, where the composition is used for chemoembolization and it may be desirable to administer a follow up dose of chemoactive agent.
  • Appropriate fillers include calcium salts, for example.
  • Part B 50% 2-acrylamido-2-methylpropane sulphonate, 2.00 g sodium salt (pH 8) Omnipaque 350 5.00 g 83 mM Fe(II) lactate 1.50 g 415 mM Ascorbic acid 0.20 g Deionized water 1.30 g
  • the prepolymer solutions Part A and Part B were delivered via a coaxial microcatheter system.
  • Solution Part A was drawn up in a mL Luer-Lok syringe then attached to the Y-connector.
  • the thread on the Y-connector (used to lock the nitinol catheter in place) was loosened.
  • the Y-connector was then back flushed with solution Part A to replace the saline (which was expelled via the loosened top thread of the Y-connector).
  • the thread on the Y-connector was retightened and injection of solution Part A was continued to allow flushing of the microcatheter. Once this was completed the syringe was removed and refilled.
  • the syringe was attached to a hand torque syringe delivery device then reattached to the Y-connect being careful to avoid the formation of air bubbles.
  • Solutions Part A and B were slowly injected through the catheters. Upon the two solutions contacting in the tip of the microcatheter hydrogel formation was initiated. The resulting polymer exited the tip of the microcatheter in a string or thread like form equal in diameter to the internal diameter of the microcatheter.
  • the two pre-polymer solutions were formulated as follows. Each solution was individually weighed or dispensed in to a 20 ml scintillation vial furnished with a magnetic stirrer bar then stirred until homogeneous. The solutions were then allowed to stand to allow any resulting air bubbles to dissipate. Part A: 30% Acrylamide functionalized PVA macromer 3.00 g Acryloxyethyl trimethylammonium chloride (80%) 0.38 g Omnipaque 350 6.10 g 415 mM Hydrogen peroxide 500 uL
  • Part B 30% Acrylamide functionalized PVA macromer 0.67 g Acryloxyethyl trimethylammonium chloride (80%) 1.25 g Omnipaque 350 6.35 g 83 mM Fe(II) lactate 1.50 g 415 mM Ascorbic acid 0.20 g
  • Example 2 A similar delivery device was used as in Example 1.
  • the inner catheter was a nitinol catheter (length 175 cm, o.d. 0.012 inches) with a spiral cut tip.
  • the mixing chamber was about 6 cm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
US10/809,140 2003-03-25 2004-03-25 Hydrogel string medical device Abandoned US20040247867A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/809,140 US20040247867A1 (en) 2003-03-25 2004-03-25 Hydrogel string medical device
US11/368,240 US7666339B2 (en) 2003-03-25 2006-03-03 Hydrogel string medical device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45773503P 2003-03-25 2003-03-25
US10/809,140 US20040247867A1 (en) 2003-03-25 2004-03-25 Hydrogel string medical device

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/368,240 Continuation US7666339B2 (en) 2003-03-25 2006-03-03 Hydrogel string medical device

Publications (1)

Publication Number Publication Date
US20040247867A1 true US20040247867A1 (en) 2004-12-09

Family

ID=33131713

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/809,140 Abandoned US20040247867A1 (en) 2003-03-25 2004-03-25 Hydrogel string medical device
US11/368,240 Active 2024-11-10 US7666339B2 (en) 2003-03-25 2006-03-03 Hydrogel string medical device

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/368,240 Active 2024-11-10 US7666339B2 (en) 2003-03-25 2006-03-03 Hydrogel string medical device

Country Status (5)

Country Link
US (2) US20040247867A1 (fr)
EP (1) EP1606009A2 (fr)
JP (1) JP2006521180A (fr)
CA (1) CA2520012A1 (fr)
WO (1) WO2004087007A2 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040193138A1 (en) * 2003-03-26 2004-09-30 Levin Howard R. Method and system to treat and prevent myocardial infarct expansion
US20050096751A1 (en) * 2003-11-01 2005-05-05 Medtronic, Inc. Implantable devices and methods for treating urinary incontinence
US20080312678A1 (en) * 2005-05-11 2008-12-18 The Board Of Regents Of The University Of Texas System Methods and Devices for Treating Obesity
US20080312744A1 (en) * 2004-07-27 2008-12-18 Edward Vresilovic Supplementation or replacement of a nucleus pulposus of an intervertebral disc
US20170007264A1 (en) * 2007-12-21 2017-01-12 Microvention, Inc. Implantation devices including hydrogel filaments
US9993252B2 (en) 2009-10-26 2018-06-12 Microvention, Inc. Embolization device constructed from expansile polymer
US10226258B2 (en) 2006-06-15 2019-03-12 Microvention, Inc. Embolization device constructed from expansile polymer
US10226533B2 (en) 2014-04-29 2019-03-12 Microvention, Inc. Polymer filaments including pharmaceutical agents and delivering same
US10232089B2 (en) 2011-04-18 2019-03-19 Terumo Corporation Embolic devices
US10471183B2 (en) 2015-12-22 2019-11-12 Access Vascular, Inc. High strength biomedical materials
US20200016381A1 (en) * 2016-09-24 2020-01-16 J.D. Franco & Co., Llc Systems and methods for single puncture percutaneous reverse blood flow
US10639396B2 (en) 2015-06-11 2020-05-05 Microvention, Inc. Polymers
US11577008B2 (en) 2017-06-21 2023-02-14 Access Vascular, Inc. High strength porous materials incorporating water soluble polymers
US11771881B2 (en) 2019-08-29 2023-10-03 Toyota Motor Engineering & Manufacturing North America, Inc. Needle adapter and device for soft material extrusion of core-shell structures
US11992627B2 (en) 2020-06-30 2024-05-28 Access Vascular, Inc. Articles comprising markings and related methods

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
US20080293637A1 (en) 2007-05-23 2008-11-27 Allergan, Inc. Cross-linked collagen and uses thereof
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
SI2818184T1 (sl) 2007-11-16 2019-03-29 Aclaris Therapeutics, Inc. Sestava in postopki za zdravljenje purpure
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
US20110135747A1 (en) * 2008-08-29 2011-06-09 Nancy Josephine Polich Homeopathic therapeutic method
EP3184552B1 (fr) 2008-09-02 2020-08-12 Tautona Group LP Fils d'acide hyaluronique, leurs procédés de fabrication et leurs utilisations
CN101721349B (zh) * 2008-10-16 2011-07-20 常州百瑞吉生物医药有限公司 可注射原位交联水凝胶及其制备方法和用途
BRPI0922629A2 (pt) 2008-12-02 2016-01-05 Allergan Inc dispositivo de injeção
DK2413894T3 (en) * 2009-04-02 2017-04-03 Allergan Inc HIGHLY FORMED HYDROGLES FOR SOFTWARE STRENGTH
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
JP5749283B2 (ja) 2010-03-12 2015-07-15 アラーガン・アンデュストリー・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎ Ｉｎｄｕｓｔｒｉｅ Ｓａｓ 皮膚状態を改善するための流体組成物
DK3078388T3 (da) 2010-03-22 2019-05-20 Allergan Inc Tværbundne hydrogeler til blødvævsforøgelse
US20130211249A1 (en) * 2010-07-22 2013-08-15 The Johns Hopkins University Drug eluting hydrogels for catheter delivery
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US10022335B2 (en) 2011-03-03 2018-07-17 Nancy Josephine Polich Homeopathic therapeutic method and compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
CN107412002A (zh) 2011-06-03 2017-12-01 阿勒根公司 包括抗氧化剂的皮肤填充剂组合物
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20140350518A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Syringe extrusion accessory
GB2520562B (en) * 2013-11-26 2017-07-26 Cook Medical Technologies Llc System and method for delivering material into a patient
EP3099253B1 (fr) 2014-01-27 2020-04-15 Allergan Holdings France S.A.S. Dispositif d'administration de substance
US10029048B2 (en) 2014-05-13 2018-07-24 Allergan, Inc. High force injection devices
US9867623B2 (en) 2014-06-05 2018-01-16 Cook Medical Technologies Llc Apparatus for delivering filamentary material into a patient
GB2528808B (en) 2014-06-05 2016-12-07 Cook Medical Technologies Llc Apparatus for delivering filamentary material into a patient
US9993253B2 (en) 2014-06-05 2018-06-12 Cook Medical Technologies Llc Dispensing device and method for delivering filamentary material into a patient
WO2016051219A1 (fr) 2014-09-30 2016-04-07 Allergan Industrie, Sas Compositions d'hydrogel stables pourvues d'additifs
US10226585B2 (en) 2014-10-01 2019-03-12 Allergan, Inc. Devices for injection and dosing
WO2016128783A1 (fr) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions et méthodes pour améliorer l'apparence de la peau
CA2976544A1 (fr) 2015-03-10 2016-09-15 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Injecteur a aiguilles multiples
CA2984614C (fr) 2015-05-06 2020-07-14 Zoetis Services Llc Formulation d'hydrogel avec adhesion legere
US10258341B2 (en) 2015-05-11 2019-04-16 Cook Medical Technologies Llc Medical assembly and device
KR102232054B1 (ko) 2016-04-08 2021-03-26 알레간 인코포레이티드 흡인 및 주입 디바이스
US10265151B2 (en) 2017-01-24 2019-04-23 Allergan Industrie Sas Thread insertion devices
US10258447B2 (en) 2017-01-24 2019-04-16 Allergan Industrie Sas Thread insertion devices
US10820900B2 (en) 2017-01-24 2020-11-03 Allergan Industrie Sas Thread insertion devices
US10709444B2 (en) 2017-01-24 2020-07-14 Allergan Industrie Sas Thread insertion devices
US10595977B2 (en) 2017-01-24 2020-03-24 Allergan Industrie, Sas Thread insertion devices
USD867582S1 (en) 2017-03-24 2019-11-19 Allergan, Inc. Syringe device

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443454A (en) * 1992-12-09 1995-08-22 Terumo Kabushiki Kaisha Catheter for embolectomy
US5508317A (en) * 1993-08-06 1996-04-16 Ciba-Geigy Corporation Photocrosslinked polymers
US5833652A (en) * 1995-09-18 1998-11-10 Y. Pierre Gobin Component mixing catheter
US6139520A (en) * 1994-08-17 2000-10-31 Boston Scientific Corporation System for implanting a cross-linked polysaccharide fiber and methods of forming and inserting the fiber
US6140452A (en) * 1994-05-06 2000-10-31 Advanced Bio Surfaces, Inc. Biomaterial for in situ tissue repair
US6152943A (en) * 1998-08-14 2000-11-28 Incept Llc Methods and apparatus for intraluminal deposition of hydrogels
US6312421B1 (en) * 1999-07-23 2001-11-06 Neurovasx, Inc. Aneurysm embolization material and device
US6558367B1 (en) * 1997-10-17 2003-05-06 Micro Therapeutics, Inc. Catheter system and method for injection of a liquid embolic composition and a solidification agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69522060T2 (de) * 1994-09-08 2002-05-29 Stryker Technologies Corp., Kalamazoo Bandscheibenkern aus Hydrogel
US5752974A (en) 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
JP4115669B2 (ja) 1998-10-01 2008-07-09 バクスター・インターナショナル・インコーポレイテッド 改良された成分混合用カテーテル
AU3503700A (en) 1999-02-25 2000-09-14 Scimed Life Systems, Inc. Medical devices comprising hydrogel polymers having improved mechanical properties
AU4977800A (en) 1999-04-26 2000-11-10 California Institute Of Technology (in situ) forming hydrogels
JP4871476B2 (ja) * 2000-03-13 2012-02-08 バイオコンパティブルズ ユーケー リミテッド 塞栓組成物
EP1392182A1 (fr) * 2001-05-04 2004-03-03 Concentric Medical Dispositif vaso-occlusif a base d'hydrogel

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443454A (en) * 1992-12-09 1995-08-22 Terumo Kabushiki Kaisha Catheter for embolectomy
US5508317A (en) * 1993-08-06 1996-04-16 Ciba-Geigy Corporation Photocrosslinked polymers
US6140452A (en) * 1994-05-06 2000-10-31 Advanced Bio Surfaces, Inc. Biomaterial for in situ tissue repair
US6139520A (en) * 1994-08-17 2000-10-31 Boston Scientific Corporation System for implanting a cross-linked polysaccharide fiber and methods of forming and inserting the fiber
US6299590B1 (en) * 1994-08-17 2001-10-09 Boston Scientific Corporation Implant, and method and device for inserting the implant
US5833652A (en) * 1995-09-18 1998-11-10 Y. Pierre Gobin Component mixing catheter
US6558367B1 (en) * 1997-10-17 2003-05-06 Micro Therapeutics, Inc. Catheter system and method for injection of a liquid embolic composition and a solidification agent
US6152943A (en) * 1998-08-14 2000-11-28 Incept Llc Methods and apparatus for intraluminal deposition of hydrogels
US6312421B1 (en) * 1999-07-23 2001-11-06 Neurovasx, Inc. Aneurysm embolization material and device

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883500B2 (en) 2003-03-26 2011-02-08 G&L Consulting, Llc Method and system to treat and prevent myocardial infarct expansion
US20040193138A1 (en) * 2003-03-26 2004-09-30 Levin Howard R. Method and system to treat and prevent myocardial infarct expansion
US20050096751A1 (en) * 2003-11-01 2005-05-05 Medtronic, Inc. Implantable devices and methods for treating urinary incontinence
US7585271B2 (en) * 2003-11-01 2009-09-08 Thd Spa Implantable devices and methods for treating urinary incontinence
US20080312744A1 (en) * 2004-07-27 2008-12-18 Edward Vresilovic Supplementation or replacement of a nucleus pulposus of an intervertebral disc
US8147553B2 (en) * 2004-07-27 2012-04-03 Synthes Usa, Llc Supplementation or replacement of a nucleus pulposus of an intervertebral disc
US20080312678A1 (en) * 2005-05-11 2008-12-18 The Board Of Regents Of The University Of Texas System Methods and Devices for Treating Obesity
US9717616B2 (en) 2005-05-11 2017-08-01 The Board Of Regents Of The University Of Texas System Methods and devices for treating obesity
US10499925B2 (en) 2006-06-15 2019-12-10 Microvention, Inc. Embolization device constructed from expansile polymer
US11185336B2 (en) 2006-06-15 2021-11-30 Microvention, Inc. Embolization device constructed from expansile polymer
US11160557B2 (en) 2006-06-15 2021-11-02 Microvention, Inc. Embolization device constructed from expansile polymer
US10226258B2 (en) 2006-06-15 2019-03-12 Microvention, Inc. Embolization device constructed from expansile polymer
US20170007264A1 (en) * 2007-12-21 2017-01-12 Microvention, Inc. Implantation devices including hydrogel filaments
US10194915B2 (en) * 2007-12-21 2019-02-05 Microvention, Inc. Implantation devices including hydrogel filaments
US9993252B2 (en) 2009-10-26 2018-06-12 Microvention, Inc. Embolization device constructed from expansile polymer
US10232089B2 (en) 2011-04-18 2019-03-19 Terumo Corporation Embolic devices
US10946100B2 (en) 2014-04-29 2021-03-16 Microvention, Inc. Polymers including active agents
US10226533B2 (en) 2014-04-29 2019-03-12 Microvention, Inc. Polymer filaments including pharmaceutical agents and delivering same
US10639396B2 (en) 2015-06-11 2020-05-05 Microvention, Inc. Polymers
US11759547B2 (en) 2015-06-11 2023-09-19 Microvention, Inc. Polymers
US10485898B2 (en) 2015-12-22 2019-11-26 Access Vascular, Inc. High strength biomedical materials
US10471183B2 (en) 2015-12-22 2019-11-12 Access Vascular, Inc. High strength biomedical materials
US11389570B2 (en) 2015-12-22 2022-07-19 Access Vascular, Inc. High strength biomedical materials
US20200016381A1 (en) * 2016-09-24 2020-01-16 J.D. Franco & Co., Llc Systems and methods for single puncture percutaneous reverse blood flow
US11690985B2 (en) * 2016-09-24 2023-07-04 J.D. Franco & Co., Llc Systems and methods for single puncture percutaneous reverse blood flow
US11577008B2 (en) 2017-06-21 2023-02-14 Access Vascular, Inc. High strength porous materials incorporating water soluble polymers
US11771881B2 (en) 2019-08-29 2023-10-03 Toyota Motor Engineering & Manufacturing North America, Inc. Needle adapter and device for soft material extrusion of core-shell structures
US11992627B2 (en) 2020-06-30 2024-05-28 Access Vascular, Inc. Articles comprising markings and related methods

Also Published As

Publication number Publication date
US20060147483A1 (en) 2006-07-06
CA2520012A1 (fr) 2004-10-14
WO2004087007A3 (fr) 2005-07-07
JP2006521180A (ja) 2006-09-21
US7666339B2 (en) 2010-02-23
WO2004087007A2 (fr) 2004-10-14
EP1606009A2 (fr) 2005-12-21

Similar Documents

Publication Publication Date Title
US7666339B2 (en) Hydrogel string medical device
USRE48302E1 (en) Embolic compositions
US11298444B2 (en) Non-degradable, low swelling, water soluble radiopaque hydrogel polymer
JP4262891B2 (ja) 腔内にヒドロゲルを投入するための装置
US20030134032A1 (en) Methods for initiating in situ formation of hydrogels
US7459142B2 (en) High viscosity embolizing compositions comprising prepolymers
WO2005067990A1 (fr) Methodes, compositions, et dispositifs d'embolisation de lumieres corporelles
AU2019270949B2 (en) Embolic compositions and methods

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOCURE, INC., GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHAOUK, HASSAN;ASFAW, BRUKTAWIT T.;REEL/FRAME:015153/0154

Effective date: 20040325

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION